Pfizer purchases Angiosyn, deal to close in first quarter

Share this article:
Pfizer has entered an agreement to buy the bio-tech start up Angiosyn which is working on a drug to help ward off blindness.
Pfizer is expected to make a small payment for the La Jolla, Calif., company upfront followed by additional payments totaling up to $527 million. The deal was expected to close in the first quarter of 2005.
The acquisition marks Pfizer's second biotechnology acquisition in about a year. Pfizer purchased Esperion Therapeutics, a start-up company working on treatments for high cholesterol, early last year.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.